As previously reported on a Current Report on Form 8-K filed on August 12, 2022, Zymeworks Inc.
(the Company or Zymeworks) filed a notice with the New York Stock Exchange on August 11, 2022 fixing August 24, 2022 as the record date for the purpose of determining the holders of the Companys common shares,
warrants and equity incentive awards (collectively, the Securityholders) entitled to receive notice of and to vote at a Special Meeting of Securityholders of the Company to be held later this year regarding the Companys proposed
redomicile transactions.
On September 1, 2022, the Company filed a notice with the New York Stock Exchange fixing October 7,
2022 as the date of the Special Meeting of Securityholders of the Company. The Special Meeting will be held on October 7, 2022, at the Pearl Room, Fairmont Pacific Rim, 1038 Canada Place, Vancouver, BC V6C 0B9, at 9 a.m., Pacific time.
Important Information for Investors and Securityholders
This communication is not intended to and does not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any
securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, purchase, or exchange of securities or solicitation of any vote or approval in any jurisdiction in contravention of applicable law. In
connection with the proposed redomicile transactions (the Redomicile Transaction), Zymeworks has caused its wholly owned subsidiary Zymeworks Delaware Inc. (Parent) to file a registration statement on Form S-4 (the Registration Statement), which includes Parents prospectus as well as Zymeworks preliminary proxy statement (the Preliminary Proxy Statement/Prospectus),
with the U.S. Securities and Exchange Commission (the SEC) and the appropriate Canadian securities regulatory authorities. Zymeworks plans to mail the definitive proxy statement/prospectus (the Definitive Proxy
Statement/Prospectus) to its shareholders and holders of its warrants and outstanding equity awards in connection with the proposed Redomicile Transaction. INVESTORS AND SECURITYHOLDERS OF ZYMEWORKS ARE URGED TO READ THE PRELIMINARY PROXY
STATEMENT/PROSPECTUS, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS (WHEN AVAILABLE) AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT ZYMEWORKS, PARENT, THE REDOMICLE TRANSACTION, AND RELATED MATTERS. Investors and securityholders will be able to obtain free copies of the Definitive Proxy Statement/Prospectus (when available) and other documents
filed with the SEC by Zymeworks or Parent through the website maintained by the SEC at www.sec.gov (EDGAR). Investors and securityholders will also be able to obtain free copies of the Definitive Proxy Statement/Prospectus (when
available) and other documents filed with Canadian securities regulatory authorities by Zymeworks, through the website maintained by the Canadian Securities Administrators at www.sedar.com (SEDAR). In addition, investors and
securityholders will be able to obtain free copies of the documents filed with the SEC and Canadian securities regulatory authorities on Zymeworks website at www.zymeworks.com or by contacting Zymeworks corporate secretary.
Participants in the Solicitation
Zymeworks and certain
of its directors, executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed Redomicile Transaction. Information regarding the persons who may, under the rules of the SEC, be deemed
participants in the solicitation of the securityholders of Zymeworks in connection with the proposed Redomicile Transaction, including a description of their respective direct or indirect interests, by security holdings or otherwise, is included in
the Preliminary Proxy Statement/Prospectus described above and will be included in the Definitive Proxy Statement/Prospectus when it is filed with the SEC and Canadian securities regulatory authorities. Additional information regarding
Zymeworks directors and executive officers is also included in Zymeworks Amendment No. 1 to the Annual Report on Form 10-K/A, which was filed with the SEC and Canadian securities
regulatory authorities on May 2, 2022. This document is available free of charge as described above.
2